# IgGenix, Inc.

> IgGenix is a clinical-stage biotechnology company in South San Francisco developing fully human, allergen-specific antibody therapeutics for severe food and environmental allergies. Its proprietary SEQ SIFTER single-cell RNA-sequencing platform isolates the rare IgE-producing B cells behind allergic reactions and re-engineers them into protective IgG antibodies designed to block the allergic cascade. The lead candidate, IGNX001, is in a Phase 1 trial for peanut allergy.

- **Founded:** 2019
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Stephen Quake (Scientific Co-Founder (Stanford)), Kari Nadeau (Scientific Co-Founder), Derek Croote (Co-Founder & Chief Technical Officer)
- **Team size:** ~6 employees
- **Products:** SEQ SIFTER Platform, IGNX001, Atopic Dermatitis Program
- **Notable:** Raised $75M total across three rounds from investors including Khosla Ventures, Alexandria Venture Investments, and Eli Lilly., Advanced IGNX001 into a Phase 1 clinical trial (ACCELERATE Peanut) for peanut allergy., Dosed first patient (Oct 2024) and completed enrollment / dosed final participant (Aug 2025) in the ACCELERATE Peanut study.

## Products & services

- **SEQ SIFTER Platform** — A proprietary single-cell RNA-sequencing discovery platform that isolates rare IgE-producing human B cells from blood and re-engineers them into fully human, high-affinity, allergen-specific IgG antibodies designed to block the allergic cascade.
- **IGNX001** — Lead antibody candidate for peanut allergy, designed to neutralize the most clinically important peanut allergens and epitopes. In Phase 1 (ACCELERATE Peanut) clinical study.
- **Atopic Dermatitis Program** — Early-stage discovery program applying the SEQ SIFTER platform to atopic dermatitis and other IgE-mediated diseases.

## Achievements

- Raised $75M total across three rounds from investors including Khosla Ventures, Alexandria Venture Investments, and Eli Lilly.
- Advanced IGNX001 into a Phase 1 clinical trial (ACCELERATE Peanut) for peanut allergy.
- Dosed first patient (Oct 2024) and completed enrollment / dosed final participant (Aug 2025) in the ACCELERATE Peanut study.
- Granted a US patent by the USPTO covering the generation of allergen-specific antibodies.
- Presented SEQ SIFTER research for its peanut program at the 2024 AAAAI Annual Meeting.
- Moved headquarters into Lilly Gateway Labs in South San Francisco.

## Latest updates

- **2025-09** — Completed enrollment for the Phase 1 ACCELERATE Peanut trial; final participant dosed August 2025.
- **2024-10** — Announced first patient dosed in the Phase 1 ACCELERATE Peanut trial evaluating IGNX001.
- **2024-02** — Presented SEQ SIFTER platform research for its peanut program at the 2024 AAAAI Annual Meeting.
- **2023-02** — Announced first close of a $40M Series B led by Alexandria Venture Investments with new investor Eli Lilly.

## Links

- Website: https://iggenix.com
- LinkedIn: http://www.linkedin.com/company/iggenix-inc
- Twitter/X: https://twitter.com/IgGenix

---

Profile page: https://yespress.io/iggenix-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-11